Sarb Shergill, Ph.D.
Vice President, Clinical Operations
Dr. Shergill joins resTORbio from Akebia Therapeutics, where she led global clinical operations, overseeing four large phase III cardiovascular outcomes studies, four Phase II studies (including studies in Japan) and several clinical pharmacology studies, as well as overseeing clinical research organization activities and managing the clinical budget.
Prior to joining Akebia Therapeutics in 2015, Dr. Shergill was an Associate Vice President of Clinical Research at Genzyme working in multiple therapeutic areas. During Dr. Shergill’s tenure at Genzyme, she led a global group of senior project leaders and led the clinical operations execution of more than 80 clinical trials (Phase I-IV). Dr. Shergill served as the Genzyme representative for many competent authority (FDA, EMA and MHRA) pre-inspection readiness initiatives as well as for regulatory inspections conducted on Genzyme products. Dr. Shergill also has experience working at a CRO and has investigator site level experience having worked in Canada for an academic teaching center running multiple studies in an ICU and multi-organ transplant setting. Dr. Shergill received her B.Sc. in Pharmacology from the University of Portsmouth, UK and her Ph.D. in Pharmacology from Liverpool John Moores University in the UK.